| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
516.00(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.31 - $12.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
36,169 |
56,771 |
56,771 |
327,734 |
| Total Sell Value |
$416,599 |
$579,645 |
$579,645 |
$5,096,867 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
3 |
4 |
4 |
23 |
| End Date |
2025-07-20 |
2025-04-18 |
2024-10-18 |
2023-10-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simpson Curran |
Chief Executive Officer |
• • – |
2025-10-09 |
4 |
AS |
$12.62 |
$262,635 |
D/D |
(20,811) |
216,162 |
|
-4% |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-09-29 |
4 |
AS |
$10.03 |
$76,469 |
D/D |
(7,624) |
236,973 |
|
19% |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-09-10 |
4 |
AS |
$10.02 |
$77,495 |
D/D |
(7,734) |
244,597 |
|
23% |
|
| Chan Mitchell |
Chief Financial Officer |
• – – |
2025-09-01 |
4 |
D |
$8.93 |
$43,766 |
D/D |
(4,901) |
53,968 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2025-09-01 |
4 |
D |
$8.93 |
$2,090 |
D/D |
(234) |
17,585 |
|
- |
|
| Christmas Patrick J. |
Chief Strategy & Legal Officer |
• – – |
2025-08-01 |
4 |
D |
$8.19 |
$38,485 |
D/D |
(4,699) |
151,411 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-07-01 |
4 |
D |
$8.23 |
$38,689 |
D/D |
(4,701) |
252,331 |
|
- |
|
| Tasse Daniel |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Stump David C |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Migausky George V |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Zachary Jennifer |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
22,064 |
|
- |
|
| Bennett Jean |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Karabelas Argeris N |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Glucksmann Alexandra |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
482,871 |
|
- |
|
| Fox Allan M. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-05-12 |
4 |
AS |
$7.91 |
$163,046 |
D/D |
(20,602) |
475,103 |
|
12% |
|
| Mills Kenneth T. |
|
– • – |
2025-05-12 |
4 |
OE |
$3.76 |
$77,464 |
D/D |
20,602 |
495,705 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-03-27 |
4 |
OE |
$3.76 |
$115,628 |
D/D |
30,752 |
475,103 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2025-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,819 |
|
39% |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$37,929 |
D/D |
(4,700) |
156,110 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$43,998 |
D/D |
(5,452) |
226,348 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$42,472 |
D/D |
(5,263) |
210,717 |
|
- |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2025-01-02 |
4 |
D |
$7.73 |
$88,083 |
D/D |
(11,395) |
160,810 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
98,912 |
257,032 |
|
- |
|
461 Records found
|
|
Page 1 of 19 |
|
|
0.61 (4.94%) 
